3-N-Butylphthalide
Butylphthalide may increase the anticoagulant activities of Epoprostenol.
Abciximab
Epoprostenol may increase the anticoagulant activities of Abciximab.
Abiraterone
The metabolism of Epoprostenol can be decreased when combined with Abiraterone.
Advertisement
Acebutolol
Acebutolol may increase the hypotensive activities of Epoprostenol.
Aceclofenac
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Aceclofenac.
Acemetacin
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Acemetacin.
Advertisement
Acenocoumarol
Epoprostenol may increase the anticoagulant activities of Acenocoumarol.
Acetyl salicylate
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Acetylsalicylic acid.
Acetyl Sulfisoxazole
The metabolism of Epoprostenol can be decreased when combined with Acetyl sulfisoxazole.
Advertisement
Adapalene
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Adapalene.
Aldesleukin
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Aldesleukin.
Alfuzosin
Alfuzosin may increase the hypotensive activities of Epoprostenol.
Aliskiren
Epoprostenol may increase the hypotensive activities of Aliskiren.
Alminoprofen
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Alminoprofen.
Aloxiprin
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Aloxiprin.
alpha Tocopherol
Vitamin E may increase the antiplatelet activities of Epoprostenol.
Alprenolol
Alprenolol may increase the hypotensive activities of Epoprostenol.
Alprostadil
Alprostadil may increase the anticoagulant activities of Epoprostenol.
Alteplase
Epoprostenol may increase the anticoagulant activities of Alteplase.
Ambrisentan
Epoprostenol may increase the hypotensive activities of Ambrisentan.
Amifostine
Epoprostenol may increase the hypotensive activities of Amifostine.
Amifostine Anhydrous
Epoprostenol may increase the hypotensive activities of Amifostine.
Amiloride
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Amiloride.
Aminosalicylic Acid
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Aminosalicylic Acid.
Amiodarone
The metabolism of Epoprostenol can be decreased when combined with Amiodarone.
Amlodipine
Amlodipine may increase the hypotensive activities of Epoprostenol.
Amobarbital
Amobarbital may increase the hypotensive activities of Epoprostenol.
Amphetamine
Amphetamine may increase the hypotensive activities of Epoprostenol.
Amphotericin B
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Epoprostenol.
amphotericin B liposomal
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Epoprostenol.
Amyl Nitrite
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Amyl Nitrite.
Anagrelide
Anagrelide may increase the anticoagulant activities of Epoprostenol.
Ancrod
Epoprostenol may increase the anticoagulant activities of Ancrod.
Anistreplase
Epoprostenol may increase the anticoagulant activities of Anistreplase.
Antipyrine
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Antipyrine.
Antithrombin III
Epoprostenol may increase the anticoagulant activities of Antithrombin III human.
Antithrombin III, Human
Epoprostenol may increase the anticoagulant activities of Antithrombin III human.
Apalutamide
The serum concentration of Epoprostenol can be decreased when it is combined with Apalutamide.
Apazone
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Azapropazone.
Apixaban
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Apixaban.
Apomorphine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Epoprostenol.
Apraclonidine
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Apraclonidine.
Apremilast
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Apremilast.
Aprepitant
The metabolism of Epoprostenol can be increased when combined with Aprepitant.
Aprotinin
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Aprotinin.
Ardeparin
Epoprostenol may increase the anticoagulant activities of Ardeparin.
Argatroban
Epoprostenol may increase the anticoagulant activities of Argatroban.
Argatroban Anhydrous
Epoprostenol may increase the anticoagulant activities of Argatroban.
Aripiprazole
Aripiprazole may increase the hypotensive activities of Epoprostenol.
Arsenic Trioxide
The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Epoprostenol.
Aspirin
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Acetylsalicylic acid.
Astaxanthin
Epoprostenol may increase the anticoagulant activities of Astaxanthin.
Atenolol
Atenolol may increase the hypotensive activities of Epoprostenol.
Avanafil
Avanafil may increase the antihypertensive activities of Epoprostenol.
Azelastine
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Azelastine.
Azilsartan
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Azilsartan medoxomil.
Azilsartan kamedoxomil
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Azilsartan medoxomil.
Azilsartan Medoxomil
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Azilsartan medoxomil.
Balsalazide
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Balsalazide.
Barbexaclone
Barbexaclone may increase the hypotensive activities of Epoprostenol.
Barbital
Barbital may increase the hypotensive activities of Epoprostenol.
Becaplermin
Epoprostenol may increase the anticoagulant activities of Becaplermin.
Bemiparin
Epoprostenol may increase the anticoagulant activities of Bemiparin.
Benazepril
Benazepril may increase the hypotensive activities of Epoprostenol.
Bendroflumethiazide
Bendroflumethiazide may increase the hypotensive activities of Epoprostenol.
Benzydamine
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Benzydamine.
Bepridil
Epoprostenol may increase the hypotensive activities of Bepridil.
Betaxolol
Betaxolol may increase the hypotensive activities of Epoprostenol.
Bethanidine
Bethanidine may increase the hypotensive activities of Epoprostenol.
Bimatoprost
Bimatoprost may increase the hypotensive activities of Epoprostenol.
Bisoprolol
Bisoprolol may increase the hypotensive activities of Epoprostenol.
Bivalirudin
Epoprostenol may increase the anticoagulant activities of Bivalirudin.
Bortezomib
The risk or severity of adverse effects can be increased when Bortezomib is combined with Epoprostenol.
Bosentan
Bosentan may increase the hypotensive activities of Epoprostenol.
Bosentan Anhydrous
Bosentan may increase the hypotensive activities of Epoprostenol.
Bretylium
Bretylium may increase the hypotensive activities of Epoprostenol.
Brimonidine
Brimonidine may increase the antihypertensive activities of Epoprostenol.
Bromfenac
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Bromfenac.
Bromocriptine
The risk or severity of adverse effects can be increased when Bromocriptine is combined with Epoprostenol.
Bufexamac
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Bufexamac.
Bumetanide
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Bumetanide.
Bupivacaine
The risk or severity of adverse effects can be increased when Bupivacaine is combined with Epoprostenol.
Bupranolol
Epoprostenol may increase the hypotensive activities of Bupranolol.
Cafedrine
Epoprostenol may increase the hypotensive activities of Cafedrine.
Canagliflozin
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Canagliflozin.
Canagliflozin Anhydrous
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Canagliflozin.
Candesartan
Epoprostenol may increase the hypotensive activities of Candesartan.
Candesartan Cilexetil
Candesartan cilexetil may increase the hypotensive activities of Epoprostenol.
Cangrelor
Epoprostenol may increase the anticoagulant activities of Cangrelor.
Capecitabine
The metabolism of Epoprostenol can be decreased when combined with Capecitabine.
Captopril
Captopril may increase the hypotensive activities of Epoprostenol.
Carbamazepine
The metabolism of Epoprostenol can be increased when combined with Carbamazepine.
Carprofen
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Carprofen.
Carteolol
Carteolol may increase the hypotensive activities of Epoprostenol.
Carvedilol
Carvedilol may increase the hypotensive activities of Epoprostenol.
Celecoxib
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Celecoxib.
Celiprolol
Epoprostenol may increase the hypotensive activities of Celiprolol.
Ceritinib
The serum concentration of Epoprostenol can be increased when it is combined with Ceritinib.
Certoparin
Epoprostenol may increase the anticoagulant activities of Certoparin.
Chloroquine
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Chloroquine.
Chlorothiazide
Chlorothiazide may increase the hypotensive activities of Epoprostenol.
Chlorpromazine
The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Epoprostenol.
Chlorthalidone
Chlorthalidone may increase the hypotensive activities of Epoprostenol.
Cholecalciferol
The metabolism of Epoprostenol can be decreased when combined with Cholecalciferol.
Choline Magnesium Trisalicyclate
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Choline magnesium trisalicylate.
Cicletanine
Epoprostenol may increase the hypotensive activities of Cicletanine.
Cilazapril
Epoprostenol may increase the hypotensive activities of Cilazapril.
Cilostazol
Cilostazol may increase the anticoagulant activities of Epoprostenol.
Citric Acid
Epoprostenol may increase the anticoagulant activities of Citric Acid.
Citric Acid, Anhydrous
Epoprostenol may increase the anticoagulant activities of Citric Acid.
Clevidipine
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Clevidipine.
Clevidipine butyrate
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Clevidipine.
Clofarabine
The risk or severity of adverse effects can be increased when Clofarabine is combined with Epoprostenol.
Clomipramine
The risk or severity of adverse effects can be increased when Clomipramine is combined with Epoprostenol.
Clonidine
Clonidine may increase the hypotensive activities of Epoprostenol.
Clonixin
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Clonixin.
Clopidogrel
Clopidogrel may increase the anticoagulant activities of Epoprostenol.
Clotrimazole
The metabolism of Epoprostenol can be decreased when combined with Clotrimazole.
Clozapine
The risk or severity of adverse effects can be increased when Clozapine is combined with Epoprostenol.
COLLAGENASE
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Collagenase clostridium histolyticum.
collagenase Clostridium histolyticum
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Collagenase clostridium histolyticum.
Conivaptan
The risk or severity of adverse effects can be increased when Conivaptan is combined with Epoprostenol.
Crisaborole
The metabolism of Epoprostenol can be decreased when combined with Crisaborole.
Cryptenamine
Cryptenamine may increase the hypotensive activities of Epoprostenol.
Curcumin
The metabolism of Epoprostenol can be decreased when combined with Curcumin.
Cyclopenthiazide
Epoprostenol may increase the hypotensive activities of Cyclopenthiazide.
Cyclosporine
The metabolism of Epoprostenol can be decreased when combined with Cyclosporine.
Cyclothiazide
Cyclothiazide may increase the hypotensive activities of Epoprostenol.
Dabigatran Etexilate
Epoprostenol may increase the anticoagulant activities of Dabigatran etexilate.
Dabrafenib
The serum concentration of Epoprostenol can be decreased when it is combined with Dabrafenib.
Dalteparin
Epoprostenol may increase the anticoagulant activities of Dalteparin.
Danaparoid
Epoprostenol may increase the anticoagulant activities of Danaparoid.
Dapagliflozin
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Dapagliflozin.
Dasatinib
Dasatinib may increase the anticoagulant activities of Epoprostenol.
Dasatinib Anhydrous
Dasatinib may increase the anticoagulant activities of Epoprostenol.
Debrisoquin
Debrisoquin may increase the hypotensive activities of Epoprostenol.
Defibrotide
Epoprostenol may increase the anticoagulant activities of Defibrotide.
Delavirdine
The metabolism of Epoprostenol can be decreased when combined with Delavirdine.
Deoxycholate
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Deoxycholic Acid.
Deoxycholic Acid
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Deoxycholic Acid.
Deserpidine
Epoprostenol may increase the hypotensive activities of Deserpidine.
Desflurane
The risk or severity of adverse effects can be increased when Desflurane is combined with Epoprostenol.
Desirudin
Epoprostenol may increase the anticoagulant activities of Desirudin.
Dexmedetomidine
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Dexmedetomidine.
Dextran
Epoprostenol may increase the anticoagulant activities of Dextran.
Diazoxide
Diazoxide may increase the hypotensive activities of Epoprostenol.
Dichlorphenamide
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Diclofenamide.
Diclofenac
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Diclofenac.
Dicumarol
Epoprostenol may increase the anticoagulant activities of Dicoumarol.
Diflunisal
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Diflunisal.
Digoxin
The serum concentration of Digoxin can be increased when it is combined with Epoprostenol.
Dihydralazine
Dihydralazine may increase the hypotensive activities of Epoprostenol.
Diltiazem
Diltiazem may increase the hypotensive activities of Epoprostenol.
Dinutuximab
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Dinutuximab.
Dipyridamole
Dipyridamole may increase the anticoagulant activities of Epoprostenol.
Dipyrone
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Metamizole.
Dorzolamide
Dorzolamide may increase the hypotensive activities of Epoprostenol.
Dothiepin
The metabolism of Epoprostenol can be decreased when combined with Dosulepin.
Doxazosin
Doxazosin may increase the hypotensive activities of Epoprostenol.
Drotrecogin Alfa
Epoprostenol may increase the anticoagulant activities of Drotrecogin alfa.
Droxicam
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Droxicam.
Duloxetine
Epoprostenol may increase the orthostatic hypotensive activities of Duloxetine.
Edetic Acid
Epoprostenol may increase the anticoagulant activities of Edetic Acid.
Edoxaban
Epoprostenol may increase the anticoagulant activities of Edoxaban.
Efavirenz
The metabolism of Epoprostenol can be decreased when combined with Efavirenz.
Empagliflozin
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Empagliflozin.
Enalapril
Enalapril may increase the hypotensive activities of Epoprostenol.
Enalaprilat
Epoprostenol may increase the hypotensive activities of Enalaprilat.
Enalaprilat Anhydrous
Epoprostenol may increase the hypotensive activities of Enalaprilat.
Enoxaparin
Epoprostenol may increase the anticoagulant activities of Enoxaparin.
Enoxaparin sodium
Epoprostenol may increase the anticoagulant activities of Enoxaparin.
Epinastine
Epinastine may increase the anticoagulant activities of Epoprostenol.
Eplerenone
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Eplerenone.
Eprosartan
Eprosartan may increase the hypotensive activities of Epoprostenol.
Eptifibatide
Eptifibatide may increase the anticoagulant activities of Epoprostenol.
Esmolol
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Esmolol.
Etanercept
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Etanercept.
Ethacrynate
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Etacrynic acid.
Ethacrynic Acid
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Etacrynic acid.
Ethylenediaminetetraacetate
Epoprostenol may increase the anticoagulant activities of Edetic Acid.
Etodolac
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Etodolac.
Etofenamate
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Etofenamate.
Etoricoxib
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Etoricoxib.
Etravirine
The metabolism of Epoprostenol can be decreased when combined with Etravirine.
Evening primrose oil
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Evening primrose oil.
Felbinac
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Felbinac.
Felodipine
Felodipine may increase the hypotensive activities of Epoprostenol.
Fenbufen
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Fenbufen.
Fenoldopam
Fenoldopam may increase the hypotensive activities of Epoprostenol.
Fenoprofen
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Fenoprofen.
Ferulic Acid
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Ferulic acid.
Fibrinolysis Inhibitor
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Aprotinin.
Floctafenine
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Floctafenine.
Floxuridine
The metabolism of Epoprostenol can be decreased when combined with Floxuridine.
Fluconazole
The metabolism of Epoprostenol can be decreased when combined with Fluconazole.
Fluindione
Epoprostenol may increase the anticoagulant activities of Fluindione.
Fluorouracil
The metabolism of Epoprostenol can be decreased when combined with Fluorouracil.
Flurbiprofen
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Flurbiprofen.
Fluvastatin
The metabolism of Epoprostenol can be decreased when combined with Fluvastatin.
Fluvoxamine
The metabolism of Epoprostenol can be decreased when combined with Fluvoxamine.
Fondaparinux sodium
Epoprostenol may increase the anticoagulant activities of Fondaparinux sodium.
Fosinopril
Fosinopril may increase the hypotensive activities of Epoprostenol.
Fosphenytoin
The metabolism of Epoprostenol can be increased when combined with Fosphenytoin.
Fostamatinib
Fostamatinib may increase the antihypertensive activities of Epoprostenol.
Furazolidone
Furazolidone may increase the hypotensive activities of Epoprostenol.
Furosemide
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Furosemide.
Gemfibrozil
The metabolism of Epoprostenol can be decreased when combined with Gemfibrozil.
Glucosamine
Glucosamine may increase the antiplatelet activities of Epoprostenol.
Guanabenz
Guanabenz may increase the hypotensive activities of Epoprostenol.
Guanadrel
Guanadrel may increase the hypotensive activities of Epoprostenol.
Guanethidine
Guanethidine may increase the hypotensive activities of Epoprostenol.
Guanfacine
Guanfacine may increase the hypotensive activities of Epoprostenol.
Halothane
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Halothane.
Heparin
Epoprostenol may increase the anticoagulant activities of Heparin.
Hexobarbital
Hexobarbital may increase the hypotensive activities of Epoprostenol.
Hydralazine
Hydralazine may increase the hypotensive activities of Epoprostenol.
Hydrochlorothiazide
Hydrochlorothiazide may increase the hypotensive activities of Epoprostenol.
Hydroflumethiazide
Hydroflumethiazide may increase the hypotensive activities of Epoprostenol.
Hydroxytyrosol
Hydroxytyrosol may increase the anticoagulant activities of Epoprostenol.
Ibritumomab Tiuxetan
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Ibritumomab tiuxetan.
Ibrutinib
The risk or severity of adverse effects can be increased when Ibrutinib is combined with Epoprostenol.
Ibuprofen
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Ibuprofen.
Icatibant
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Icatibant.
Icosapent Ethyl
Icosapent ethyl may increase the anticoagulant activities of Epoprostenol.
Ifenprodil
Ifenprodil may increase the anticoagulant activities of Epoprostenol.
Iloprost
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Iloprost.
Imidapril
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Imidapril.
Imipramine
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Imipramine.
Indapamide
Indapamide may increase the hypotensive activities of Epoprostenol.
Indinavir
The metabolism of Epoprostenol can be decreased when combined with Indinavir.
INDINAVIR ANHYDROUS
The metabolism of Epoprostenol can be decreased when combined with Indinavir.
Indobufen
Epoprostenol may increase the anticoagulant activities of Indobufen.
Indomethacin
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Indomethacin.
Indoramin
Indoramin may increase the hypotensive activities of Epoprostenol.
Iproniazid
Iproniazid may increase the hypotensive activities of Epoprostenol.
Irbesartan
The metabolism of Epoprostenol can be decreased when combined with Irbesartan.
Isocarboxazid
Isocarboxazid may increase the hypotensive activities of Epoprostenol.
Isoflurane
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Isoflurane.
Isosorbide Dinitrate
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Isosorbide Dinitrate.
Isosorbide Mononitrate
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Isosorbide Mononitrate.
Isoxsuprine
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Isoxsuprine.
Isradipine
Isradipine may increase the hypotensive activities of Epoprostenol.
Kebuzone
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Kebuzone.
Ketanserin
Ketanserin may increase the anticoagulant activities of Epoprostenol.
Ketoconazole
The metabolism of Epoprostenol can be decreased when combined with Ketoconazole.
Ketoprofen
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Ketoprofen.
Ketorolac
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Ketorolac.
Labetalol
Labetalol may increase the hypotensive activities of Epoprostenol.
Lacidipine
Epoprostenol may increase the hypotensive activities of Lacidipine.
Latanoprost
Latanoprost may increase the hypotensive activities of Epoprostenol.
Leflunomide
The metabolism of Epoprostenol can be decreased when combined with Leflunomide.
Lepirudin
Epoprostenol may increase the anticoagulant activities of Lepirudin.
Lercanidipine
Lercanidipine may increase the hypotensive activities of Epoprostenol.
Levobunolol
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Levobunolol.
Levobupivacaine
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Levobupivacaine.
Levodopa
Epoprostenol may increase the orthostatic hypotensive activities of Levodopa.
Levosimendan
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Levosimendan.
Limonene, (+)-
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with (4R)-limonene.
Lisinopril
Lisinopril may increase the hypotensive activities of Epoprostenol.
Lisinopril Anhydrous
Lisinopril may increase the hypotensive activities of Epoprostenol.
Lofexidine
Epoprostenol may increase the hypotensive activities of Lofexidine.
Lornoxicam
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Lornoxicam.
Losartan
The metabolism of Epoprostenol can be decreased when combined with Losartan.
Lovastatin
The metabolism of Epoprostenol can be decreased when combined with Lovastatin.
Loxoprofen
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Loxoprofen.
Lumacaftor
The serum concentration of Epoprostenol can be decreased when it is combined with Lumacaftor.
Macitentan
Epoprostenol may increase the hypotensive activities of Macitentan.
Magnesium Salicylate
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Magnesium salicylate.
Manidipine
Epoprostenol may increase the hypotensive activities of Manidipine.
Mannitol
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Mannitol.
Masoprocol
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Masoprocol.
Mecamylamine
Mecamylamine may increase the hypotensive activities of Epoprostenol.
Meclofenamate
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Meclofenamic acid.
Meclofenamic Acid
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Meclofenamic acid.
Mefenamic Acid
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Mefenamic acid.
Meloxicam
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Meloxicam.
Mephobarbital
Methylphenobarbital may increase the hypotensive activities of Epoprostenol.
Mepirodipine
Epoprostenol may increase the antihypertensive activities of Barnidipine.
Mesalamine
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Mesalazine.
Methazolamide
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Methazolamide.
Methohexital
Methohexital may increase the hypotensive activities of Epoprostenol.
Methyclothiazide
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Methyclothiazide.
Methyl Salicylate
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Methyl salicylate.
Methyldopa
Methyldopa may increase the hypotensive activities of Epoprostenol.
METHYLDOPA ANHYDROUS
Methyldopa may increase the hypotensive activities of Epoprostenol.
Methylene blue
Methylene blue may increase the hypotensive activities of Epoprostenol.
Methylphenidate
Methylphenidate may decrease the antihypertensive activities of Epoprostenol.
Metipranolol
Metipranolol may increase the hypotensive activities of Epoprostenol.
Metolazone
Metolazone may increase the hypotensive activities of Epoprostenol.
Metoprolol
Metoprolol may increase the hypotensive activities of Epoprostenol.
Metyrosine
Epoprostenol may increase the hypotensive activities of Metyrosine.
Mibefradil
Epoprostenol may increase the hypotensive activities of Mibefradil.
Midostaurin
The metabolism of Epoprostenol can be decreased when combined with Midostaurin.
Mifepristone
The serum concentration of Epoprostenol can be increased when it is combined with Mifepristone.
Milrinone
Milrinone may increase the anticoagulant activities of Epoprostenol.
Minaprine
Minaprine may increase the hypotensive activities of Epoprostenol.
Minoxidil
Minoxidil may increase the hypotensive activities of Epoprostenol.
Moclobemide
Moclobemide may increase the hypotensive activities of Epoprostenol.
Moexipril
Moexipril may increase the hypotensive activities of Epoprostenol.
Molsidomine
Molsidomine may increase the hypotensive activities of Epoprostenol.
Morphine
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Morphine.
Moxonidine
Moxonidine may increase the hypotensive activities of Epoprostenol.
MYCOPHENOLATE
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Mycophenolic acid.
Mycophenolate Mofetil
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Mycophenolate mofetil.
Mycophenolic Acid
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Mycophenolic acid.
Nabilone
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Nabilone.
Nabumetone
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Nabumetone.
Nadolol
Nadolol may increase the hypotensive activities of Epoprostenol.
Nadroparin
Epoprostenol may increase the anticoagulant activities of Nadroparin.
Naftifine
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Naftifine.
Naproxen
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Naproxen.
Nebivolol
Epoprostenol may increase the hypotensive activities of Nebivolol.
Nepafenac
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Nepafenac.
Nesiritide
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Nesiritide.
Nialamide
Nialamide may increase the hypotensive activities of Epoprostenol.
Nicardipine
The metabolism of Epoprostenol can be decreased when combined with Nicardipine.
Nicorandil
Nicorandil may increase the hypotensive activities of Epoprostenol.
Nifedipine
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Nifedipine.
Niflumic Acid
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Niflumic Acid.
Nilvadipine
Epoprostenol may increase the hypotensive activities of Nilvadipine.
Nimesulide
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Nimesulide.
Nimodipine
Nimodipine may increase the hypotensive activities of Epoprostenol.
Nisoldipine
Nisoldipine may increase the hypotensive activities of Epoprostenol.
Nitrendipine
Nitrendipine may increase the hypotensive activities of Epoprostenol.
Nitric Oxide
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Nitric Oxide.
Nitroglycerin
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Nitroglycerin.
Nitroprusside
Nitroprusside may increase the hypotensive activities of Epoprostenol.
Obinutuzumab
Epoprostenol may increase the hypotensive activities of Obinutuzumab.
Oenothera biennis seed extract
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Evening primrose oil.
Olmesartan
Olmesartan may increase the hypotensive activities of Epoprostenol.
Olopatadine
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Olopatadine.
Olsalazine
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Olsalazine.
Omega-3 Fatty Acids
Omega-3 fatty acids may increase the antiplatelet activities of Epoprostenol.
Omeprazole
The metabolism of Epoprostenol can be decreased when combined with Omeprazole.
Oxaprozin
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Oxaprozin.
Oxprenolol
Epoprostenol may increase the hypotensive activities of Oxprenolol.
Oxyphenbutazone
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Oxyphenbutazone.
Paclitaxel
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Paclitaxel.
Palmidrol
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Palmidrol.
Papaverine
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Papaverine.
Parecoxib
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Parecoxib.
Paregoric
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Morphine.
Pargyline
Pargyline may increase the hypotensive activities of Epoprostenol.
Parnaparin
Epoprostenol may increase the anticoagulant activities of Parnaparin.
Parthenolide
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Parthenolide.
Penbutolol
Epoprostenol may increase the hypotensive activities of Penbutolol.
Pentaerythritol Tetranitrate
Epoprostenol may increase the anticoagulant activities of Pentaerythritol Tetranitrate.
Pentobarbital
Pentobarbital may increase the hypotensive activities of Epoprostenol.
Pentosan Polysulfate
The risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Epoprostenol.
Pentoxifylline
Pentoxifylline may increase the antiplatelet activities of Epoprostenol.
Perindopril
Perindopril may increase the hypotensive activities of Epoprostenol.
Phenelzine
Phenelzine may increase the hypotensive activities of Epoprostenol.
Phenindione
Epoprostenol may increase the anticoagulant activities of Phenindione.
Phenobarbital
The metabolism of Epoprostenol can be increased when combined with Phenobarbital.
Phenoxybenzamine
Phenoxybenzamine may increase the hypotensive activities of Epoprostenol.
Phenprocoumon
Epoprostenol may increase the anticoagulant activities of Phenprocoumon.
Phentolamine
Phentolamine may increase the hypotensive activities of Epoprostenol.
Phentolamine Mesylate
Phentolamine may increase the hypotensive activities of Epoprostenol.
Phenylbutazone
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Phenylbutazone.
Phenytoin
The metabolism of Epoprostenol can be increased when combined with Phenytoin.
Phospholipids
Omega-3 fatty acids may increase the antiplatelet activities of Epoprostenol.
Pimecrolimus
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Pimecrolimus.
Pinacidil
Pinacidil may increase the hypotensive activities of Epoprostenol.
Pindolol
Pindolol may increase the hypotensive activities of Epoprostenol.
Pipamperone
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Pipamperone.
Pirfenidone
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Pirfenidone.
Piroxicam
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Piroxicam.
Piroxicam-Beta-Cyclodextrin
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Piroxicam.
Plasmin
Epoprostenol may increase the anticoagulant activities of Fibrinolysin.
Polythiazide
Epoprostenol may increase the hypotensive activities of Polythiazide.
Potassium Citrate
Epoprostenol may increase the anticoagulant activities of Potassium Citrate.
Pramipexole
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Pramipexole.
Prasugrel
Prasugrel may increase the anticoagulant activities of Epoprostenol.
Prazosin
Prazosin may increase the hypotensive activities of Epoprostenol.
Primidone
The metabolism of Epoprostenol can be increased when combined with Primidone.
Procaine
Procaine may increase the hypotensive activities of Epoprostenol.
Procarbazine
Procarbazine may increase the hypotensive activities of Epoprostenol.
Propofol
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Propofol.
Propranolol
Propranolol may increase the hypotensive activities of Epoprostenol.
protein C, human
Epoprostenol may increase the anticoagulant activities of Protein C.
protein S, human
Epoprostenol may increase the anticoagulant activities of Protein S human.
Protocatechualdehyde
Epoprostenol may increase the anticoagulant activities of Protocatechualdehyde.
Pyrimethamine
The metabolism of Epoprostenol can be decreased when combined with Pyrimethamine.
Quetiapine
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Quetiapine.
Quetiapine fumarate
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Quetiapine.
Quinapril
Quinapril may increase the hypotensive activities of Epoprostenol.
Quinine
The metabolism of Epoprostenol can be decreased when combined with Quinine.
Ramipril
Ramipril may increase the hypotensive activities of Epoprostenol.
Rasagiline
Rasagiline may increase the hypotensive activities of Epoprostenol.
Remifentanil
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Remifentanil.
Rescinnamine
Epoprostenol may increase the hypotensive activities of Rescinnamine.
Reserpine
Reserpine may increase the hypotensive activities of Epoprostenol.
Resveratrol
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Resveratrol.
Reteplase
Epoprostenol may increase the anticoagulant activities of Reteplase.
Reviparin
Epoprostenol may increase the anticoagulant activities of Reviparin.
Reviparin sodium
Epoprostenol may increase the anticoagulant activities of Reviparin.
Rifampin
The metabolism of Epoprostenol can be increased when combined with Rifampicin.
Rifapentine
The metabolism of Epoprostenol can be increased when combined with Rifapentine.
Rilmenidine
Rilmenidine may increase the hypotensive activities of Epoprostenol.
Riociguat
Epoprostenol may increase the hypotensive activities of Riociguat.
Risperidone
Epoprostenol may increase the hypotensive activities of Risperidone.
Rituximab
Epoprostenol may increase the hypotensive activities of Rituximab.
Rivaroxaban
Epoprostenol may increase the anticoagulant activities of Rivaroxaban.
Rofecoxib
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Rofecoxib.
Ropinirole
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Ropinirole.
Ropivacaine
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Ropivacaine.
Rosiglitazone
Epoprostenol may increase the anticoagulant activities of Rosiglitazone.
Rotigotine
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Rotigotine.
Rucaparib
The metabolism of Epoprostenol can be decreased when combined with Rucaparib.
Sacubitril
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Sacubitril.
Salicylamide
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Salicylamide.
Salicylic Acid
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Salicylic acid.
Salsalate
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Salsalate.
Secobarbital
The metabolism of Epoprostenol can be increased when combined with Secobarbital.
Selegiline
Selegiline may increase the hypotensive activities of Epoprostenol.
Selexipag
Epoprostenol may increase the anticoagulant activities of Selexipag.
Serratiopeptidase
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Serrapeptase.
Sevoflurane
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Sevoflurane.
Sildenafil
Sildenafil may increase the antihypertensive activities of Epoprostenol.
Sodium Citrate
Epoprostenol may increase the anticoagulant activities of Sodium Citrate.
Sorafenib
The metabolism of Epoprostenol can be decreased when combined with Sorafenib.
Sotalol
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Sotalol.
Spirapril
Epoprostenol may increase the hypotensive activities of Spirapril.
Spironolactone
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Spironolactone.
Streptokinase
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Streptokinase.
Sufentanil
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Sufentanil.
Sulfadiazine
The metabolism of Epoprostenol can be decreased when combined with Sulfadiazine.
Sulfamethoxazole
The metabolism of Epoprostenol can be decreased when combined with Sulfamethoxazole.
Sulfasalazine
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Sulfasalazine.
Sulfisoxazole
The metabolism of Epoprostenol can be decreased when combined with Sulfisoxazole.
Sulindac
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Sulindac.
Suprofen
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Suprofen.
Tadalafil
Tadalafil may increase the antihypertensive activities of Epoprostenol.
Talinolol
Epoprostenol may increase the hypotensive activities of Talinolol.
Tamsulosin
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Tamsulosin.
Telmisartan
Telmisartan may increase the hypotensive activities of Epoprostenol.
Tenecteplase
Epoprostenol may increase the anticoagulant activities of Tenecteplase.
Tenoxicam
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Tenoxicam.
Terazosin
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Terazosin.
Teriflunomide
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Teriflunomide.
Terlipressin
Epoprostenol may increase the hypotensive activities of Terlipressin.
Thalidomide
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Thalidomide.
Theodrenaline
Epoprostenol may increase the hypotensive activities of Theodrenaline.
Theophylline
Theophylline may increase the antihypertensive activities of Epoprostenol.
Theophylline anhydrous
Theophylline may increase the antihypertensive activities of Epoprostenol.
Thiamylal
Thiamylal may increase the hypotensive activities of Epoprostenol.
Thiopental
Thiopental may increase the hypotensive activities of Epoprostenol.
Thiopental Sodium
Thiopental may increase the hypotensive activities of Epoprostenol.
Thioridazine
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Thioridazine.
Tiaprofenic Acid
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Tiaprofenic acid.
Tibolone
Epoprostenol may increase the hypotensive activities of Tibolone.
Ticagrelor
The metabolism of Epoprostenol can be decreased when combined with Ticagrelor.
Ticlopidine
The metabolism of Epoprostenol can be decreased when combined with Ticlopidine.
Timolol
Timolol may increase the hypotensive activities of Epoprostenol.
Timolol Anhydrous
Timolol may increase the hypotensive activities of Epoprostenol.
Tinzaparin
Epoprostenol may increase the anticoagulant activities of Tinzaparin.
Tinzaparin sodium
Epoprostenol may increase the anticoagulant activities of Tinzaparin.
Tipranavir
Tipranavir may increase the antiplatelet activities of Epoprostenol.
Tirofiban
Tirofiban may increase the anticoagulant activities of Epoprostenol.
Tizanidine
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Tizanidine.
Tolazoline
Tolazoline may increase the hypotensive activities of Epoprostenol.
Tolbutamide
The metabolism of Epoprostenol can be decreased when combined with Tolbutamide.
Tolcapone
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Tolcapone.
Tolfenamic Acid
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Tolfenamic Acid.
Tolmetin
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Tolmetin.
Toloxatone
Toloxatone may increase the hypotensive activities of Epoprostenol.
Torsemide
Torasemide may increase the hypotensive activities of Epoprostenol.
Tositumomab
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Tositumomab.
Trandolapril
Trandolapril may increase the hypotensive activities of Epoprostenol.
Tranilast
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Tranilast.
Tranylcypromine
Tranylcypromine may increase the hypotensive activities of Epoprostenol.
Trapidil
Trapidil may increase the anticoagulant activities of Epoprostenol.
Travoprost
Travoprost may increase the hypotensive activities of Epoprostenol.
Treprostinil
Epoprostenol may increase the anticoagulant activities of Treprostinil.
Tretinoin
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Tretinoin.
Triamterene
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Triamterene.
Tribenoside
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Tribenoside.
Trichlormethiazide
Trichlormethiazide may increase the hypotensive activities of Epoprostenol.
Triflusal
Epoprostenol may increase the anticoagulant activities of Triflusal.
Trimethaphan
Trimethaphan may increase the hypotensive activities of Epoprostenol.
Trimethoprim
The metabolism of Epoprostenol can be decreased when combined with Trimethoprim.
Trisodium Citrate Anhydrous
Epoprostenol may increase the anticoagulant activities of Sodium Citrate.
Trolamine Salicylate
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Trolamine salicylate.
Troxerutin
Epoprostenol may increase the anticoagulant activities of Troxerutin.
UNOPROSTONE
Epoprostenol may increase the hypotensive activities of Unoprostone.
Urapidil
Urapidil may increase the hypotensive activities of Epoprostenol.
Urokinase
Epoprostenol may increase the anticoagulant activities of Urokinase.
Valdecoxib
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Valdecoxib.
Valproate
The metabolism of Epoprostenol can be decreased when combined with Valproic Acid.
Valproic Acid
The metabolism of Epoprostenol can be decreased when combined with Valproic Acid.
Valsartan
The metabolism of Epoprostenol can be decreased when combined with Valsartan.
Vardenafil
Vardenafil may increase the antihypertensive activities of Epoprostenol.
Verapamil
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Verapamil.
Vincamine
Epoprostenol may increase the hypotensive activities of Vincamine.
Vinpocetine
Epoprostenol may increase the hypotensive activities of Vinpocetine.
Vitamin E
Vitamin E may increase the antiplatelet activities of Epoprostenol.
Vorapaxar
Vorapaxar may increase the anticoagulant activities of Epoprostenol.
Voriconazole
The metabolism of Epoprostenol can be decreased when combined with Voriconazole.
Warfarin
Epoprostenol may increase the anticoagulant activities of Warfarin.
Xylometazoline
Epoprostenol may increase the hypotensive activities of Xylometazoline.
Yohimbine
Yohimbine may decrease the antihypertensive activities of Epoprostenol.
Zafirlukast
The metabolism of Epoprostenol can be decreased when combined with Zafirlukast.
Zileuton
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Zileuton.
Zofenopril
Epoprostenol may increase the hypotensive activities of Zofenopril.
Zomepirac
The therapeutic efficacy of Epoprostenol can be decreased when used in combination with Zomepirac.
![Pulmonary Arterial Hypertension [PAH] - Symptoms & Signs - Causes - Diagnosis - Treatment](https://www.medindia.net/images/common/patientinfo/120_100/pulmonary-arterial-hypertension-pah.jpg "Pulmonary Arterial Hypertension [PAH] - Symptoms & Signs - Causes - Diagnosis - Treatment")
